Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Genmab ( (GMAB) ) has issued an announcement.
On November 6, 2025, Genmab announced its financial results for the first nine months of 2025, reporting a 21% increase in revenue to $2,662 million, driven by higher royalties from DARZALEX and Kesimpta. The company also revealed its proposed acquisition of Merus N.V., a move expected to enhance its late-stage portfolio and accelerate its growth as a global biotechnology leader. This acquisition, valued at approximately $8 billion, is anticipated to close by early 2026, subject to customary conditions.
The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s overall stock score reflects strong financial performance and promising earnings call highlights, including significant revenue growth and strategic pipeline investments. Technical analysis shows mixed signals, while valuation remains reasonable. Despite recent revenue and cash flow challenges, the company’s strategic direction and clinical successes provide a positive outlook.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is a biotechnology company based in Denmark, focusing on the development of antibody therapeutics for cancer treatment. The company is known for its innovative pipeline and collaborations with major pharmaceutical companies like Johnson & Johnson and Novartis.
Average Trading Volume: 2,059,491
Technical Sentiment Signal: Buy
Current Market Cap: $17.92B
Learn more about GMAB stock on TipRanks’ Stock Analysis page.